

Kura Oncology, Inc.
12730 High Bluff Drive
Suite 400
San Diego, CA 92130
(858) 500-8800

August 14, 2020

VIA EDGAR

United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Jeffrey Gabor

Re: Kura Oncology, Inc.

**Registration Statement on Form S-3
File No. 333-241663**

Ladies and Gentlemen:

Kura Oncology, Inc. (the “*Registrant*”) hereby requests that the Securities and Exchange Commission (the “*Commission*”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective at 4:00 p.m. Eastern Time on Tuesday, August 18, 2020, or as soon thereafter as is practicable. The Registrant also hereby requests a copy of the written order verifying the effective date.

If you have any questions regarding this request, please contact Charles J. Bair of Cooley LLP at (858) 550-6142.

Sincerely,

KURA ONCOLOGY, INC.

By: /s/ Marc Grasso

Marc Grasso, M.D.
Chief Financial Officer and Chief Business Officer

cc: Charles J. Bair, Cooley LLP